Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

H Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd Announce Results of Phase II Clinical Data for Lu AE58054 in Alzheimer Disease


Tuesday, 16 Jul 2013 02:28pm EDT 

H Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd announced that the first clinical data on the investigational drug Lu AE58054 in Alzheimer’s disease demonstrated that treatment with Lu AE58054 as add-on to donepezil for six months improved cognitive performance in patients with moderate Alzheimer’s disease. Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone. Lundbeck and Otsuka will initiate a phase III clinical program in about 3,000 patients during the second half of 2013. 

Company Quote

125.0
-2.6 -2.04%
10:59am EDT